Novartis (NVS) announced that it has successfully completed its acquisition of Tourmaline Bio (TRML). With the completion of the acquisition, shares of the common stock of Tourmaline have ceased trading on the Nasdaq Stock Market and Tourmaline is now an indirect wholly owned subsidiary of Novartis. “The acquisition of Tourmaline Bio aligns with our strategy to deepen expertise in areas where Novartis can lead and add value in cardiovascular innovation. Pacibekitug’s differentiated anti-IL-6 mechanism offers a scientifically compelling approach to residual inflammation – a key driver of atherosclerotic cardiovascular disease. We look forward to collaborating with Tourmaline’s team to further advance this promising asset and continue strengthening our ability to deliver potentially transformative therapies for diseases with high unmet need,” said Shreeram Aradhye, M.D., President of Development and Chief Medical Officer at Novartis.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Novartis announces expiration of Tourmaline Bio tender offer
- Tourmaline Bio’s Promising Phase 2b Study on Thyroid Eye Disease Treatment
- Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer
- Novartis Stock (NVS) Pops as U.S. Approves Pill to Treat Stubborn Skin Flare-Ups
- Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis